Kancera AB (publ)
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the … Read more
Kancera AB (publ) (KAN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.227x
Based on the latest financial reports, Kancera AB (publ) (KAN) has a cash flow conversion efficiency ratio of -0.227x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-9.80 Million) by net assets (Skr43.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kancera AB (publ) - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Kancera AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kancera AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kancera AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Forbidden Foods Ltd
AU:FFF
|
-0.112x |
|
Oscar Properties Holding AB
ST:OP
|
0.151x |
|
Lord Resources Ltd
AU:LRD
|
-0.317x |
|
MetaVia Inc.
NASDAQ:MTVA
|
-0.467x |
|
Universal Biosensors Inc
AU:UBI
|
-0.301x |
|
Asiabasemetals Inc
V:ABZ
|
-0.004x |
|
Puri Global Sukses Tbk Pt
JK:PURI
|
-0.151x |
|
Alakasa Industrindo Tbk
JK:ALKA
|
0.034x |
Annual Cash Flow Conversion Efficiency for Kancera AB (publ) (2010–2024)
The table below shows the annual cash flow conversion efficiency of Kancera AB (publ) from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr62.30 Million | Skr-58.53 Million | -0.940x | +19.56% |
| 2023-12-31 | Skr47.66 Million | Skr-55.67 Million | -1.168x | -162.54% |
| 2022-12-31 | Skr106.91 Million | Skr-47.56 Million | -0.445x | -23.54% |
| 2021-12-31 | Skr122.54 Million | Skr-44.12 Million | -0.360x | +43.47% |
| 2020-12-31 | Skr72.28 Million | Skr-46.05 Million | -0.637x | +66.66% |
| 2019-12-31 | Skr17.42 Million | Skr-33.29 Million | -1.911x | -41.51% |
| 2018-12-31 | Skr33.36 Million | Skr-45.04 Million | -1.350x | +2.37% |
| 2017-12-31 | Skr38.71 Million | Skr-53.54 Million | -1.383x | -256.36% |
| 2016-12-31 | Skr59.52 Million | Skr-23.10 Million | -0.388x | +58.81% |
| 2015-12-31 | Skr21.93 Million | Skr-20.66 Million | -0.942x | -34.58% |
| 2014-12-31 | Skr27.29 Million | Skr-19.11 Million | -0.700x | -99.93% |
| 2013-12-31 | Skr18.96 Million | Skr-6.64 Million | -0.350x | +92.89% |
| 2012-12-31 | Skr5.50 Million | Skr-27.08 Million | -4.925x | -449.52% |
| 2011-12-31 | Skr25.90 Million | Skr-23.21 Million | -0.896x | -75.76% |
| 2010-12-31 | Skr11.07 Million | Skr-5.64 Million | -0.510x | -- |